Anticalins: inhalable biologicals for severe asthma

这笔赠款旨在开发一种名为“抗菌素”的新药。抗菌素的作用就像一类成功的药物，称为单抗(MAbs)。单抗太脆弱，太大，不能吸入治疗肺部疾病，但抗菌素很小，很健壮。我们将开发一种安替卡林(PRS-060)，它可以阻止严重哮喘患者的破坏性免疫反应。通过吸入PRS-060，我们希望制造一种新的、临床上有用的药物来治疗一种常见的控制不佳的严重哮喘。

This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.